FDA approves Actavis’ generic opioid dependence drug

Actavis announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Reckitt Benckiser’s Subutex® (Buprenorphine 2 mg and 8 mg sublingual tablets). Actavis intends to begin shipping its product shortly. Subutex® is indicated for the treatment of opioid dependence. For the 12 months ending December 31, 2014, Subutex® had total U.S. sales of approximately $108 million, according to IMS Health data.

Read the source article at THE MEDICAL NEWS

About the Author

Leave a Reply